The role of neoadjuvant chemotherapy in the management of primary breast cancer

Minerva Ginecologica

Volumn 63, Issue 3, 2011, Pages 261-274

  Aigner, J ^a   Schneeweiss, A ^a   Sohn, C ^a   Marme F ^a  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

Breast neoplasms; Chemotherapy, adjuvant; Lymph nodes

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; EVEROLIMUS; FLUOROURACIL; LAPATINIB; METHOTREXATE; PACLITAXEL; PERTUZUMAB; PLATINUM; TRASTUZUMAB;

ADJUVANT CHEMOTHERAPY; AXILLARY LYMPH NODE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER SURGERY; CLINICAL TRIAL (TOPIC); COMORBIDITY; DIAGNOSTIC PROCEDURE; DRUG DOSE REDUCTION; DRUG EFFICACY; HUMAN; MULTIPLE CYCLE TREATMENT; PRIMARY TUMOR; REVIEW; TREATMENT RESPONSE; TRIPLE NEGATIVE BREAST CANCER;

AXILLA; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; LYMPHATIC METASTASIS; NEOADJUVANT THERAPY; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 79961007100     PISSN: 00264784     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (62)

1. Rastogi P, Anderson SJ, Bear HD, Geyer CE, Kahlenberg MS, Robidoux A et al. Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. J Clin Oncol 2008;26:778-85.
2. Gianni L, Baselga J, Eiermann W, Porta VG, Semiglazov V, Lluch A et al. Phase III Trial Evaluating the Addition of Paclitaxel to Doxorubicin Followed by Cyclophosphamide, Methotrexate, and Fluorouracil, as Adjuvant or Primary Systemic Therapy: European Cooperative Trial in Operable Breast Cancer. J Clin Oncol 2009;19:2567.
3. Mauri D, Pavlidis N, Ioannidis JP. Neoadjuvant versus adjuvant systemic treatment in breast cancer: a metaanalysis. J Natl Cancer Institute 2005;97:188-94. (Pubitemid 40277368)
4. Kaufmann M, von Minckwitz G, Bear HD, Buzdar A, McGale P, Bonnefoi H et al. Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives 2006. Ann Oncol 2007;18:1927-34.
5. Untch M FP, Konecny GE, Hasmueller S, Lebeau A, Kreienberg R, Camara O et al. Pathological Complete Response after Neoadjuvant Chemotherapy + Trastuzumab Treatment Predicts Survival and Detects a Patient Subgroup at High Need for Improvement of Anti-HER2 Therapy. Three Year Median Follow-Up Data of the TECHNO Trial. SABCS 2010 Poster presented at the 33rd San Antonio Breast Cancer Symposium, San Antonio TX; 8.-12. December 2010, 2010
6. Liedtke C, Mazouni C, Hess KR, André F, Tordai A, Mejia JA et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol 2008;26:1275-81.
7. Mazouni C, Peintinger F, Wan-Kau S, Andre F, Gonzalez-Angulo AM, Symmans WF et al. Residual ductal carcinoma in situ in patients with complete eradication of invasive breast cancer after neoadjuvant chemotherapy does not adversely affect patient outcome. J Clin Oncol 2007;25:2650-5. (Pubitemid 47123169)
8. Bear HD, Anderson S, Smith RE, Geyer CE Jr, Mamounas EP, Fisher B et al. Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer:National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 2006;24:2019-27. (Pubitemid 46622110)
9. Gianni L, Eiermann W, Semiglazov V, Manikhas A, Lluch A, Tjulandin S et al. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet 2010;375:377-84.
10. Albain KS, Barlow WE, Ravdin PM, Farrar WB, Burton GV, Ketchel SJ et al. Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node-positive breast cancer: a phase 3, open-label, randomised controlled trial. Lancet 2009;374:2055-63.
11. von Minckwitz G, Rezai M, Loibl S, Fasching PA, Huober J, Tesch H et al. Capecitabine in addition to anthracycline- and taxane-based neoadjuvant treatment in patients with primary breast cancer: phase III GeparQuattro study. J Clin Oncol 2010;28:2015-23.
12. O'Shaughnessy J. First efficacy results of a randomized, open-label, phase iii study of adjuvant doxorubicin plus cyclophosphamide, followed by docetaxel with or without capecitabine, in high-risk early breast cancer. Cancer Res 2010;72:S2-4.
13. Kuerer HM, Newman LA, Smith TL, Ames FC, Hunt KK, Dhingra K et al. Clinical Course of Breast Cancer Patients With Complete Pathologic Primary Tumor and Axillary Lymph Node Response to Doxorubicin-Based Neoadjuvant Chemotherapy. J Clin Oncol 1999;17:460-9. (Pubitemid 29075229)
14. Hennessy BT, Hortobagyi GN, Rouzier R, et al: Outcome after pathologic complete eradication of cytologically proven breast cancer axillary node metastases following primary chemotherapy. J Clin Oncol 23:9304-11, 2005
15. Krag DN, Anderson SJ, Julian TB, Brown AM, Harlow SP, Costantino JP et al. Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial. Lancet Oncol 2010;11:927-33.
16. Mamounas EP, Brown A, Anderson S, Smith R, Julian T, Miller B et al. Sentinel node biopsy after neoadjuvant chemotherapy in breast cancer: results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 2005;23:2694-702. (Pubitemid 46179459)
17. Classe JM, Bordes V, Campion L, Mignotte H, Dravet F, Leveque J et al. Sentinel lymph node biopsy after neoadjuvant chemotherapy for advanced breast cancer: results of Ganglion Sentinelle et Chimiotherapie Neoadjuvante, a French prospective multicentric study. J Clin Oncol 2009;27:726-32.
18. Tausch C, Konstantiniuk P, Kugler F, Reitsamer R, Roka S, Pöstlberger S et al. Sentinel lymph node biopsy after preoperative chemotherapy for breast cancer: findings from the Austrian Sentinel Node Study Group. Ann Surg Oncol 2008;15:3378-83.
19. Krag DN, Anderson SJ, Julian TB, Brown AM, Harlow SP, Costantino JP et al. Technical outcomes of sentinel-lymph-node resection and conventional axillary-lymph-node dissection in patients with clinically node-negative breast cancer: results from the NSABP B-32 randomised phase III trial. Lancet Oncol 2007;8:881-8.
20. Giuliano AE, Hunt KK, Ballman KV, Beitsch PD, Whitworth PW, Blumencranz PW et al. Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. JAMA 2011;305:569-75.
21. Giuliano AE, McCall L, Beitsch P, Whitworth PW, Blumencranz P, Leitch AM et al. Locoregional recurrence after sentinel lymph node dissection with or without axillary dissection in patients with sentinel lymph node metastases: the American College of Surgeons Oncology Group Z0011 randomized trial. Ann Surg 2010;252:426-32.
22. Kuehn T, Fehm T, Fleige B, Helms G, Liedtke C, Mail M et al. Sentinel node biopsy before or after neoadjuvant systemic treatment - The German SENTINA Trial. . Cancer Research 69:Abstracts: Thirty-Second Annual CTRC-AACR San Antonio Breast Cancer Symposium- Dec 10-13, 2009; San Antonio, TX, 2010
23. Perou CM, Parker JS, Prat A, Ellis MJ, Bernard PS. Clinical implementation of the intrinsic subtypes of breast cancer. Lancet Oncol 2010;11:718-9.
24. Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA et al. Molecular portraits of human breast tumours. Nature 2000;406:747-52.
25. Prat A, Parker JS, Karginova O, Fan C, Livasy C, Herschkowitz JI et al. Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res 2010;12:R68.
26. Parker JS, Mullins M, Cheang MC, Leung S, Voduc D, Vickery T et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol 2009;27:1160-7.
27. Parker J. A supervised risk predictor of breast cancer based on biological subtypes. J Clin Oncol (Meeting Abstracts) 2008;26:abstr. 11008.
28. Park SY, Kim KS, Lee TG, Park SS, Kim SM, Han W et al. The accuracy of preoperative core biopsy in determining histologic grade, hormone receptors, and human epidermal growth factor receptor 2 status in invasive breast cancer. Am J Sur 2009;197:266-9.
29. Lebeau A, Turzynski A, Braun S, Behrhof W, Fleige B, Schmitt WD et al. Reliability of human epidermal growth factor receptor 2 immunohistochemistry in breast core needle biopsies. J Clin Oncol 2010;28:3264-70.
30. Tsuda H, Kurosumi M, Umemura S, Yamamoto S, Kobayashi T, Osamura RY et al. HER2 testing on core needle biopsy specimens from primary breast cancers: interobserver reproducibility and concordance with surgically resected specimens. BMC Cancer 2010;10:534.
31. Kwok TC, Rakha EA, Lee AH, Grainge M, Green AR, Ellis IO et al. Histological grading of breast cancer on needle core biopsy: the role of immunohistochemical assessment of proliferation. Histopathology 2010;57: 212-9.
32. von Wasielewski R, Klöpper K, Lück HJ, Kreipe H. [Improvement of breast cancer grading in punch biopsies: grading with the Ki-67 marker]. Pathologe 2006;27:337-45.
33. Goldhirsch A, Ingle JN, Gelber RD, Coates AS, Thürlimann B, Senn HJ; Panel members. Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2009. Ann Oncol 2009;20:1319-29.
34. Martin M, Segui MA, Antón A, Ruiz A, Ramos M, Adrover E et al. Adjuvant docetaxel for high-risk, node-negative breast cancer. New Engl J Med 2010;363:2200-10.
35. Laporte SJ, Chapelle C, Jacquin J, Martin M. Consistency of effect of docetaxel-containing adjuvant chemotherapy in patients with early stage breast cancer independent of nodal status: meta-analysis of 12 randomized clinical trials. Cancer Research 2009;69:abstract 605.
36. De Laurentiis M, Cancello G, D'Agostino D, Giuliano M, Giordano A, Montagna E et al. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials. J Clin Oncol 2008;26:44-53.
37. Abe H, Schmidt RA, Kulkarni K, Sennett CA, Mueller JS, Newstead GM. Axillary lymph nodes suspicious for breast cancer metastasis: sampling with US-guided 14-gauge core-needle biopsy-clinical experience in 100 patients. Radiology 2009;250:41-9.
38. Alkuwari E, Auger M. Accuracy of fine-needle aspiration cytology of axillary lymph nodes in breast cancer patients: a study of 115 cases with cytologic-histologic correlation. Cancer 2008;114:89-93. (Pubitemid 351640787)
39. Koelliker SL, Chung MA, Mainiero MB, Steinhoff MM, Cady B. Axillary lymph nodes: US-guided fine-needle aspiration for initial staging of breast cancer-correlation with primary tumor size. Radiology 2008;246:81-9.
40. Untch M, Möbus V, Kuhn W, Muck BR, Thomssen C, Bauerfeind I et al. Intensive dose-dense compared with conventionally scheduled preoperative chemotherapy for high-risk primary breast cancer. J Clin Oncol 2009;27:2938-45.
41. Untch M, Fasching PA, Konecny GE, von Koch F, Conrad U, Fett W et al. PREPARE trial: a randomized phase III trial comparing preoperative, dose-dense, dose-intensified chemotherapy with epirubicin, paclitaxel and CMF versus a standard-dosed epirubicin/ cyclophosphamide followed by paclitaxel {+/-} darbepoetin alfa in primary breast cancer-results at the time of surgery. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO, 2011. Ann Oncol 2011 Mar [Epub ahead of print].
42. Untch M, von Minckwitz G, Konecny GE, von Koch F, Conrad U, Fett W et al. PREPARE trial: a randomized phase III trial comparing preoperative, dose-dense, dose-intensified chemotherapy with epirubicin, paclitaxel, and CMF versus a standard-dosed epirubicin-cyclophosphamide followed by paclitaxel with or without darbepoetin alfa in primary breast cancer-outcome on prognosis. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO, 2011. Ann Oncol 2011 Mar [Epub ahead of print].
43. Citron ML, Berry DA, Cirrincione C, Hudis C, Winer EP, Gradishar WJ et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 2003;21:1431-9. (Pubitemid 46594092)
44. Moebus V, Jackisch C, Lueck HJ, du Bois A, Thomssen C, Kurbacher C et al. Intense dose-dense sequential chemotherapy with epirubicin, paclitaxel, and cyclophosphamide compared with conventionally scheduled chemotherapy in high-risk primary breast cancer: mature results of an AGO phase III study. J Clin Oncol 2010;28:2874-80.
45. van der Hage JA, van de Velde CJ, Julien JP, Tubiana-Hulin M, Vandervelden C et al. Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902. J Clin Oncol2001;19:4224-37.
46. Fisher B, Brown A, Mamounas E, Wieand S, Robidoux A, Margolese RG et al. Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol 1997;15:2483-93. (Pubitemid 27289876)
47. von Minckwitz G, Kummel S, Vogel P, Hanusch C, Eidtmann H, Hilfrich J et al. Neoadjuvant vinorelbine-capecitabine versus docetaxel-doxorubicin- cyclophosphamide in early nonresponsive breast cancer: phase III randomized GeparTrio trial. J Natl Cancer Inst 2008;100:542-51.
48. Buzdar AU, Ibrahim NK, Francis D, Booser DJ, Thomas ES, Theriault RL et al. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol 2005;23:3676-85.
49. Buzdar AU, Valero V, Ibrahim NK, Francis D, Broglio KR, Theriault RL et al. Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized study population and data of additional patients treated with the same regimen. Clin Cancer Res 2007;13:228-33.
50. Untch M SD, Konecny G, Kreienberg R, Thommsen C, Camara OMV, Kuehn T, DuBois A et al. A multicenter phase II study of preoperative epirubicin, cyclophosphamide (EC) followed by paclitaxel (P) plus trastuzumab (T) in Her2 positive primary breast cancer. Paper presented at: 28th Annual San Antonio Breast Cancer; 8-11 December 2005 Abstract 1064, 2005
51. von Minckwitz G KM, Kümmel S, Fasching P, Eiermann W, Blohmer J-U, Costa SD et al. Integrated meta-analysis on 6402 patients with early breast cancer receiving neoadjuvant anthracycline-taxane +/- trastuzumab containing chemotherapy, SABCS - San Antonio Breast Cnacer Symposium. San Antonio, 2008
52. Coudert BP, Largillier R, Arnould L, Chollet P, Campone M, Coeffic D et al. Multicenter phase II trial of neoadjuvant therapy with trastuzumab, docetaxel, and carboplatin for human epidermal growth factor receptor-2-overexpressing stage II or III breast cancer: results of the GETN(A)-1 trial. J Clin Oncol 2007;25:2678-84. (Pubitemid 47123173)
53. Silver DP, Richardson AL, Eklund AC, Wang ZC, Szallasi Z, Li Q et al. Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer. J Clin Oncol 2010;28:1145-53.
54. Ryan PD, Isakoff SJ, Golshan M, Richardson A, Corben AD, Smith BL et al. Garber: neoadjuvant cisplatin and bevacizumab in triple negative breast cancer (TNBC): Safety and efficacy. J Clin Oncol (Meeting Abstracts) 2009;27:abstr 551.
55. Sirohi B, Arnedos M, Popat S, Ashley S, Nerurkar A, Walsh G et al. Platinum-based chemotherapy in triple-negative breast cancer. Ann Oncol 2008;19:1847-52.
56. Frasci G, Cornelia P, Rinaldo M, Iodice G, Di Bonito M, D'Aiuto M Preoperative weekly cisplatin-epirubicin-paclitaxel with G-CSF support in triple-negative large operable breast cancer. Ann Oncol 2009;20:1185-92.
57. Torrisi R, Balduzzi A, Ghisini R, Rocca A, Bottiglieri L, Giovanardi F et al. Tailored preoperative treatment of locally advanced triple negative (hormone receptor negative and HER2 negative) breast cancer with epirubicin, cisplatin, and infusional fluorouracil followed by weekly paclitaxel. Cancer Chemother Pharmacol 2008;62:667-72.
58. von Minckwitz GEH, Rezai M, Fasching PA, Tesch H, Eggemann H, Schrader I et al. Neoadjuvant chemotherapy with or without bevacizumab: primary efficacy endpoint analysis of the GEPARQUINTO Study (GBG 44). Cancer Research (Abstracts: Thirty-Third Annual CTRC-AACR San Antonio Breast Cancer Symposium- Dec 8-12, 2010; San Antonio, TX) 70:abstract S4-6, 2010
59. O'Shaughnessy J, Diéras V, Byrtek M, Duenne A-A, Miles D: Meta-analysis of patientswith triple-negative breast cancer from three randomized trials of first-line bevacizumab and chemotherapy treatment for metastatic breast cancer poster presented at the 33rd San Antonio Breast Cancer Symposium, San Antonio, Texas, 2010
60. Gelmon HWH, Robidoux A, Tonkin KS, Tischkowitz M, Swenerton K, Huntsman D et al. Can we define tumors that will respond to PARP inhibitors? A phase II correlative study of olaparib in advanced serous ovarian cancer and triple-negative breast cancer. J Clin Oncol (Meeting Abstracts) 28:abstr. 3002, 2010
61. Isakoff S, Bo J, Tung NM, Gelman RS, Giranda VL, Bernhard KM et al. Goss: A phase II trial of the PARP inhibitor veliparib (ABT888) and temozolomide for metastatic breast cancer. J Clin Oncol 2010 (Meeting Abstracts) 28:abstr 1019.
62. O'Shaughnessy J, Osborne C, Pippen JE, Yoffe M, Patt D, Rocha et al. Iniparib plus chemotherapy in metastatic triple-negative breast cancer. N Engl J Med 2011;364:205-14.